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Among 6789 HIV-infected Zambian adults screened for hep-
atitis B virus (HBV) coinfection, estimated glomerular ﬁltra-
tion rate (eGFR) was 50–90 mL/minute/1.73 m2 in 17.6%
and <50 mL/minute/1.73 m2 in 2.5%. Human immunodeﬁ-
ciency virus/HBV coinfection was associated with eGFR
<50 mL/minute/1.73 m2 (adjusted odds ratio, 1.96 [95% con-
ﬁdence interval, 1.34–2.86]), adjusted for age, sex, CD4+
count, and World Health Organization disease stage.
Keywords. HIV/AIDS; hepatitis B virus; renal dysfunction;
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Approximately 3 million human immunodeﬁciency virus
(HIV)-infected individuals in sub-Saharan Africa (SSA) are
chronically coinfected with hepatitis B virus (HBV) [1]. HIV/
HBV coinfection is associated with increased incidence of
serum aminotransferase elevations, delayed CD4+ count recov-
ery, and increased all-cause mortality during antiretroviral ther-
apy (ART) compared with HIV alone [2, 3]. Another potential
complication of HIV/HBV coinfection is renal dysfunction.
HBV monoinfection causes various forms of kidney disease
[4], but little is known about HBV-related kidney disease in
the setting of HIV, particularly in SSA. Comorbid kidney dis-
ease in the setting of HIV/HBV is challenging to manage clin-
ically because the preferred antiretroviral agent in coinfection,
tenofovir disoproxil fumarate (TDF), is potentially nephrotoxic
[5]. We investigated the prevalence of renal impairment among
HIV-infected Zambian adults with and without HBV coinfec-
tion at the time of enrollment in HIV care.
METHODS
In their 2010 HIV treatment guidelines, the Zambian Ministry
of Health recommended routine HBV screening of patients at
the time of linkage to care [6].During 2011–2013, this guideline
was implemented among public-sector HIV care and treatment
facilities in Zambia’s capital, Lusaka [7]. We analyzed data from
HIV-infected adults who enrolled in clinics that had the highest
uptake of HBV screening during that time period. HBV testing
took place at a reference laboratory using an enzyme-linked im-
munoassay (Access 2 Analyzer, Beckman Coulter) for the hep-
atitis B surface antigen (HBsAg).
Other enrollment procedures included World Health Orga-
nization (WHO) AIDS clinical staging and the measurement
of hemoglobin, CD4+ T-cell count, creatinine, and alanine ami-
notransferase (ALT). For this analysis, we deﬁned an elevated
ALT level as grade 2 or higher according to the Division of
AIDS criteria [8]. Using a single creatinine measurement
made at enrollment and prior to receipt of any antiretroviral
drugs (Olympus AU400 Analyzer, Beckman Coulter), we calcu-
lated each patient’s estimated glomerular ﬁltration rate (eGFR)
with the Chronic Kidney Disease Epidemiology Collaboration
formula [9]. We deﬁned tuberculosis coinfection as having
been referred to HIV care during tuberculosis treatment.
Using logistic regression, we modeled the factors associated
with being screened for HBV at enrollment. We then deter-
mined the proportion of HBV-screened patients with chronic
HBV coinfection, deﬁned by having a single positive HBsAg
test. We compared patient characteristics using the Wilcoxon
rank-sum test for continuous variables and the χ2 test for
categorical variables, according to HBV status. We categori-
zed eGFR as normal (>90 mL/minute/1.73 m2) [10], mildly
impaired (50–90 mL/minute/1.73 m2), and moderate/severely
impaired (<50 mL/minute/1.73 m2) [11]. To explore the associ-
ation between HBV coinfection and eGFR <50 mL/minute/
1.73 m2—the degree of impairment where TDF is relatively
contraindicated—we ﬁt a multivariable logistic regression
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model considering HBV coinfection as the primary exposure
variable and including possible confounders including age,
sex, WHO clinical stage, and CD4+ count. Under a subgroup
analysis of the HBV-coinfected individuals, we assessed wheth-
er an elevated ALT level, a surrogate of liver disease, was asso-
ciated with an eGFR <50 mL/minute/1.73 m2.
In a sensitivity analysis, we estimated GFR using the Modiﬁ-
cation of Diet in Renal Disease (MDRD) study equation [12].
Prior to use, the dataset was stripped of personal identifying in-
formation. We used Stata version 12 for analysis (StataCorp,
College Station, Texas). The ethics committees of the University
of Zambia and the University of North Carolina at Chapel Hill
approved our use of programmatic data in this analysis.
RESULTS
From January 2011 to December 2013, within 7 Lusaka urban
district facilities, 6839 of 13 138 (52.1%) HIV-infected adults
were screened for HBV at enrollment into HIV care. Initial
ALT level and CD4+ T-cell count were not associated with
being screened for HBV coinfection (both P > .05), but age
≥30 years (adjusted odds ratio [AOR], 1.11; 95% conﬁdence in-
terval [CI], 1.03–1.20), male sex (AOR, 1.14; 95% CI, 1.06–
1.23), and WHO stage 1 or 2 (AOR, 1.32; 95% CI, 1.22–1.43)
were associated with an increased likelihood of HBsAg screen-
ing. Patients with tuberculosis were less likely to be tested for
HBsAg (AOR, 0.70; 95% CI, .62–.80).
Among HBsAg-tested patients, 50 (0.7%) had unavailable re-
sults due to insufﬁcient specimen volume, and the remaining
patients (N = 6789) comprised the analysis cohort. Among
the analysis cohort, the median age was 34 years (interquartile
range [IQR], 28–40), 56% were women, and 799 (11.8%) were
HBV coinfected. Men were more likely than women to be HBV
coinfected (14.6% vs 9.5%, P < .001). HBV-coinfected patients
had lower median CD4+ counts (194 vs 252 cells/µL) and
were more likely to have tuberculosis coinfection (9.9% vs
6.9%) compared to those with HIV alone (all P < .001).
At enrollment, the median eGFR among those in the analysis
cohort was 111 mL/minute/1.73 m2 (IQR, 94–129); 1195
(17.6%) had an eGFR of 50–90 mL/minute/1.73 m2, and 172
(2.5%) patients had an eGFR <50 mL/minute/1.73 m2. Factors
associated with eGFR <50 were increased age, male sex, reduced
CD4+ count, WHO stage 3 or 4, and HBV coinfection (all
P < .001; Table 1). Compared to those infected with HIV
alone, HIV/HBV-coinfected patients had 2-fold odds of
eGFR<50 mL/minute/1.73 m2 (4.9% vs 2.2%, P < .001). After
adjustment for age, sex, CD4+ count, and WHO stage, HBV co-
infection remained associated with an eGFR <50 mL/minute/
1.73 m2 (AOR, 1.96; 95% CI, 1.34–2.86; Table 1).
Among HIV-HBV patients, 61 (7.7%) had an elevated ALT
level at enrollment compared with 158 (2.7%) in the HIV-
monoinfected group. Independent of age, sex, CD4+ count,
and WHO stage, an elevated ALT level was associated with an
eGFR <50 mL/minute/1.73 m2 among HIV/HBV-coinfected
patients (AOR, 4.03; 95% CI, 1.60–10.13). When we repeated
analyses using the MDRD formula, the proportion of patients
with renal impairment and the association between HBsAg
and eGFR <50 mL/minute/1.73 m2 was similar (Supplementary
Table 1).
DISCUSSION
Among HIV-infected Zambian adults in this analysis, HBV co-
infection was associated with increased odds of baseline eGFR
<50 mL/minute/1.73 m2, the threshold at which TDF use is dis-
couraged by the WHO’s HIV treatment guidelines. Interesting-
ly, HIV/HBV-coinfected patients with elevated ALT levels
appeared more likely to have an eGFR <50 mL/minute/1.73
m2, suggesting a possible link between HBV-related liver disease
activity and renal dysfunction.
Strengths of our study included its relatively large size and its
external validity for primary care settings in SSA. We also note
several limitations. Our study was limited by its cross-sectional
nature. As our analysis relied on the initial eGFR at enrollment,
we could not distinguish acute from chronic kidney disease. Al-
though HBV is an established cause of renal disease, we were
Table 1. Risk Factors for Baseline Moderate/Severe Renal
Dysfunction Among 6789 HIV-Infected Zambian Adults
Risk
Factor
No. (%) With
Renal
Dysfunction
Bivariable
Analysis,OR
(95% CI)
Multivariable
Analysis,OR
(95% CI)
HBV coinfection
No 133 (2.2) 1 1
Yes 39 (4.9) 2.26 (1.57–3.25) 1.96 (1.34–2.86)
Age, y
16–39 80 (1.6) 1 1
40–49 54 (4.0) 2.59 (1.82–3.68) 2.32 (1.63–3.32)
≥50 38 (8.1) 5.41 (3.63–8.06) 5.01 (3.32–7.55)
Sex
Female 71 (1.9) 1 1
Male 101 (3.4) 1.84 (1.36–2.51) 1.34 (.97–1.84)
WHO clinical stage
1–2 62 (1.4) 1 1
3–4 110 (4.4) 3.16 (2.30–4.33) 2.07 (1.49–2.89)
CD4+ count, cells/µL
≥200 24 (1.2) 1 1
50–200 47 (4.8) 3.81 (2.62–5.52) 2.89 (1.98–4.24)
<50 24 (7.7) 6.11 (3.99–9.36) 4.06 (2.60–6.34)
Estimated glomerular filtration rate of <50 mL/minute/1.73 m2 was based on
the Chronic Kidney Disease Epidemiology Collaboration formula.
Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HIV, human
immunodeficiency virus; OR, odds ratio; WHO, World Health Organization.
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unable to attribute causality to HBV coinfection. We adjusted
models for factors known to be associated with impaired renal
function in HIV patients, but unobserved factors may have re-
sulted in residual confounding. In addition, urinalysis and/or
renal biopsy data would have strengthened our study as it may
have allowed us to differentiate HBV-associated nephropathy
from HIV-associated kidney diseases; however, such diagnostic
tests are limited in settings such as ours. In the period of our anal-
ysis, only 52% of HIV care enrollees were screened for HBsAg.
Although a patient’s initial ALT level was not associated, the
probability of HBsAg testing increased with age, a risk factor
for eGFR <50 mL/minute/1.73 m2. Therefore, we could not ex-
clude selection bias as a factor in the observed association be-
tween HBV and renal dysfunction.
Nevertheless, our results suggest that HBV coinfection may
be an important risk factor for renal disease in HIV-infected in-
dividuals and that the degree of HBV-related liver disease may
be associated with renal dysfunction. At HIV care enrollment,
the likelihood of an eGFR <50 mL/minute/1.73 m2 was doubled
for patients with HIV/HBV coinfection, and was even higher in
the subset of dually infected patients with an elevated ALT.
These results support others in the medical literature. In
France, among 137 HIV/HBV-coinfected patients in a well-
characterized cohort study, investigators demonstrated that
signiﬁcant hepatic ﬁbrosis, based on the Fibrometer score,
was associated with increased risk of developing renal
impairment during ART (adjusted hazard ratio, 3.74; 95% CI,
1.57–8.92) [13]. However, among 114 HIV/HBV-coinfected
participants in a clinical trial, despite being more likely to
experience an eGFR decline compared to those with HIV
alone, HBV DNA level, hyaluronic acid, AST-to-platelet ratio,
and FIB-4 were not associated with the likelihood of kidney dis-
ease development [14]. More investigation is needed to conﬁrm
our ﬁndings and to delineate which HBV-coinfected patients
are at highest risk to develop renal disease.
Although only 5% of HIV/HBV-coinfected patients had
an eGFR <50 mL/minute/1.73 m2 in our study, an estimated
3 million dually infected patients live in resource-constrained
settings. For this reason, guidelines are needed to address the
management of this challenging clinical scenario. Whenever
HIV infection is complicated by an eGFR <50 mL/minute/
1.73 m2, WHO and Zambian guidelines recommend non-
TDF-containing regimens that include either lamivudine or
emtricitabine [11]. This is suboptimal in HIV/HBV coinfection
because resistant HBV viruses emerge when either is the sole
HBV-active agent in the regimen. Dose adjustment of TDF is
also possible, but this is unlikely to be a widely implementable
strategy in overburdened ART programs where ﬁxed-dose com-
bination pills are predominant. Unfortunately, entecavir, a drug
that is often used in such situations in upper-income settings, is
rarely available in SSA.
In summary, in this Lusaka cohort, HBV coinfection was as-
sociated with having an eGFR <50 mL/minute/1.73 m2, the
threshold at which TDF should be withheld per guidelines.
Additional investigation and clinical guidance is needed for re-
source-constrained settings with signiﬁcant HIV/HBV burden.
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